|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Herpes Simplex | |||||
| 2 | More general conditions related to this trial | ||||
| DNA Virus Infections | |||||
| Herpesviridae Infections | |||||
| Skin Diseases | |||||
| Skin Diseases, Infectious | |||||
| Skin Diseases, Viral | |||||
| Virus Diseases | |||||
| 3 | Interventions listed in this trial | ||||
| Valaciclovir | |||||
| 4 | Additional drug interventions recognized in this trial | ||||
| Valacyclovir | |||||
| 5 | More general drug interventions related to this trial | ||||
| Anti-Infective Agents | |||||
| Antiviral Agents | |||||
| Pharmacologic Actions | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| National Institute of Allergy and Infectious Diseases (NIAID) | |||||